Delivery Order 36F79724D0185-36C24526F0342
Award Date 8/4/26
Potential Completion Date 9/30/26
Potential Value $23K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, specifically Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Migalastat (Galafold 123 mg) on April 29, 2026. This firm fixed-price delivery order, with an ultimate completion date of May 29, 2026, represents a child order under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract (36F79724D0185). The contract carries no set-aside...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 28, 2026, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule for Galafold 123 mg. Performance is at Philadelphia, PA, with an ultimate completion date of May 4, 2026. The parent vehicle is the GSA Federal Supply Schedule contract (FSS-61-IB), a multiple-award schedule enabling VA networks nationwide to procure pharmaceutical products including enzyme replacement...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on July 1, 2026, for Galafold (migalastat) 123 mg under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is Philadelphia, PA 19104. The order is due July 7, 2026. The requirement is for Galafold 123 mg capsules, an FDA-approved enzyme replacement therapy indicated for treatment of Fabry disease in veterans. Pricing is firm fixed price with no...
- Veterans Integrated Service Network 7 issued a $228,396.10 delivery order to Amicus Therapeutics US, LLC on February 23, 2026, for Galafold medication under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The parent Federal Supply Schedule contract, effective through August 31, 2029, enables VISNs across the Department of Veterans Affairs to procure Galafold (migalastat) 123 mg, an FDA-approved enzyme replacement therapy for Fabry disease treatment. Place of performance is...
- The Department of Veterans Affairs, Veterans Integrated Service Network 21 (VISN 21), awarded a delivery order valued at $22,839.61 to Amicus Therapeutics US, LLC for the supply of Migalastat (Galafold 123 mg), an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, awarded on March 13, 2026, with an ultimate completion date of April 13, 2026, represents one of over 150 task orders placed under Amicus Therapeutics' parent Federal...
- On December 9, 2025, the Department of Veterans Affairs' Veterans Integrated Service Network 9 (VISN 9) awarded a delivery order to Amicus Therapeutics US, LLC for an emergency pharmaceutical buy valued at $65,673.63. This firm fixed-price delivery order, with an ultimate completion date of February 1, 2026, falls under the parent Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract (36F79724D0185), valued at $13.0 million and valid through August 31, 2029. The delivery order...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 7, 2026, for Galafold 123 mg under the GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB). The parent contract is a multiple-award Federal Supply Schedule vehicle (36F79724D0185) valued at $13.024 million, effective through August 31, 2029, enabling VA medical centers nationwide to procure specialized pharmaceutical products. Place of performance is Philadelphia, PA. The order is firm...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $18,888.46 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule to Amicus Therapeutics US, LLC for an emergency buy of Galafold (migalastat). As the parent company, Amicus Therapeutics, Inc. will support product delivery. Performance will occur in Philadelphia, Pennsylvania. This schedule allows federal agencies to procure a wide range of pharmaceutical...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on November 20, 2025, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order, with no set-aside designation, represents a task order placed under Amicus Therapeutics' existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The...
- The Department of Veterans Affairs Veterans Health Administration has awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc., to provide the specialty medication Galafold (migalastat) under the GSA's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The potential value of this delivery order is $63,268.41, and it is intended to fulfill the VA's pharmaceutical requirements to support healthcare...